Marion Maetens - Laboratory for Translational Breast Cancer Research (LTBCR), KU Leuven

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 156 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Figure S1 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: an Analysis of the ZEPHIR Clinical Trial

Mattia Rediti,Danai Fimereli,Magdalena Mileva,Zéna Wimana,David Venet,Patrick Flamen,Thomas Guiot,Elisabeth G.E. de Vries,Carolien P. Schröder, Catharina Willemien Menke-van der Houven van Oordt,Marion Maetens,Samira Majjaj,Denis Larsimont,Françoise Rothé,Christos Sotiriou,Géraldine Gebhart

crossref（2025）

Cited0Views0Bibtex

Supplementary Table S2 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: an Analysis of the ZEPHIR Clinical Trial

crossref（2025）

Cited0Views0Bibtex

Histopathological Insights into Metastatic Breast Cancer Gained from Rapid Autopsies

Gitte Zels, Anirudh Pabba, Maxim De Schepper, Tatjana Geukens, Karen Van Baelen,Marion Maetens,Amena Mahdami, Sophia Leduc,Edoardo Isnaldi, Ha-Linh Nguyen, Imane Bachir, Josephine Van Cauwenberge, Kristien Borremans,Birgit Weynand, Elia Biganzoli,Patrick Neven,Hans Wildiers, Wouter Van Den Bogaert,François Richard,Christine Desmedt,Giuseppe Floris

Laboratory investigation a journal of technical methods and pathologypp.104202-104202, (2025)

Cited0Views0WOSBibtex

Supplementary Figure S4 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: an Analysis of the ZEPHIR Clinical Trial

crossref（2025）

Cited0Views0Bibtex

Supplementary Table S7 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: an Analysis of the ZEPHIR Clinical Trial

crossref（2025）

Cited0Views0Bibtex

Supplementary Figure S3 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: an Analysis of the ZEPHIR Clinical Trial

crossref（2025）

Cited0Views0Bibtex

Prognostic Relation of Body Mass Index on Extended Aromatase Inhibition Treatment in Postmenopausal Patients with Estrogen Receptor Positive Breast Cancer: A Retrospective Analysis of the SOLE Trial

Giacomo Biganzoli,Edoardo Isnaldi,François Richard,Giuseppe Marano,Patrizia Boracchi,Marion Maetens,Giuseppe Floris,Patrick Neven,Guy Jerusalem,Elisabetta Munzone,Erika Hitre,Andrea Gombos,Alastair Thompson, Stefan Aebi,Roswitha Kammler,Patrizia Dell'Orto,Giuseppe Viale,Meredith M Regan, Marco Colleoni, Elia Biganzoli,Christine Desmedt

European journal of cancer (Oxford, England 1990) (2025): 115438-115438

Cited0Views0WOSBibtex

Supplementary Figure S5 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: an Analysis of the ZEPHIR Clinical Trial

crossref（2025）

Cited0Views0Bibtex

Supplementary Table S9 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: an Analysis of the ZEPHIR Clinical Trial

crossref（2025）

Cited0Views0Bibtex

Supplementary Figure S6 from Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: an Analysis of the ZEPHIR Clinical Trial

crossref（2025）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn